Medistim

Regulatory Filings • Aug 23, 2017

Preliminary findings from the REQUEST registry study presented at the ICC in New York, USA

Preliminary findings from the REQUEST registry study presented at the ICC in New York, USA

(Oslo, August 23rd, 2017) Medistim ASA (OSE: MEDI), a niche market

leader within ultrasound technology with headquarter in Norway, that

develops and commercializes medical equipment for use within

cardiac, vascular and transplant surgery, announces that preliminary

findings from the REQUEST registry study were presented at the 3rd

International Coronary Conference, ICC, in New York, USA, this

weekend.

The REQUEST study is a prospective, multicenter registry with

leading cardiac surgery centers from Europe, USA and Canada, led by

Coordinating Investigator Professor David Taggart from the

University of Oxford. The objective is to study how often the

combination of high-resolution ultrasound imaging and transit time

flow measurements (TTFM) performed with Medistim's VeriQC or MiraQ

devices will change the surgical procedure. The surgical coronary

artery bypass grafting (CABG) protocol includes ultrasound scanning

of the aorta, conduit, target coronary vessel and anastomosis as

well as TTFM graft assessment. The study is unique, since data from

such a protocol have never been collected before.

The hypothesis motivating the REQUEST registry study is that

employing this combination of functional flow measurement and

morphological ultrasound imaging data will enable surgeons to make

better-informed decisions during coronary surgery, and thereby

improve surgical quality, outcomes and ultimately, contribute to

improved healthcare efficiency from this surgical procedure.

The endpoints for the study are any change in planned surgical

procedure, type of procedure adaptation, number of graft revisions

and adverse events.

Professor Taggart presented the first preliminary results from the

776 patients included so far showing that 26% of the patient

population had one or more surgical changes made to the procedure

based on imaging and flow data. "This is a high number, which

indicates that the addition of high-resolution ultrasound imaging is

indeed helpful in guiding the CABG procedure, even for highly

experienced surgeons", says Professor Taggart. "It will be of

considerable interest to evaluate the data from the full 1000

patient population and learn more about how the imaging and flow

techniques can help guide CABG surgery during the various stages of

the procedure."

"We believe this is a very significant number of changes, that

speaks to the value of adding imaging to flow measurements during

CABG surgical planning and graft assessment", says Medistim CEO Kari

E. Krogstad. "The study is progressing well and we look forward to

analyzing the final data set."

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: thomas.jakobsen@medistim.com

About Medistim

Medistim was established in 1984, and has a track record of

profitable growth over the past >10 years. The company is a pioneer

within its segment, and continues to invest in new product

development. Medistim has wholly owned subsidiaries with sales

organizations in the US, Germany, Denmark, UK, Spain and Norway, in

addition to the about 50 distributors in Europe, Asia, Middle East,

Africa and South America. For more information, visit the Medistim

home page: www.Medistim.com

This information is disclosed under Norwegian law

(Verdipapirhandelloven §5-12).